[go: up one dir, main page]

GB201002409D0 - Methods - Google Patents

Methods

Info

Publication number
GB201002409D0
GB201002409D0 GBGB1002409.9A GB201002409A GB201002409D0 GB 201002409 D0 GB201002409 D0 GB 201002409D0 GB 201002409 A GB201002409 A GB 201002409A GB 201002409 D0 GB201002409 D0 GB 201002409D0
Authority
GB
United Kingdom
Prior art keywords
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1002409.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nottingham
Original Assignee
University of Nottingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nottingham filed Critical University of Nottingham
Priority to GBGB1002409.9A priority Critical patent/GB201002409D0/en
Publication of GB201002409D0 publication Critical patent/GB201002409D0/en
Priority to PCT/GB2011/050233 priority patent/WO2011098806A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/11Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
GBGB1002409.9A 2010-02-12 2010-02-12 Methods Ceased GB201002409D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1002409.9A GB201002409D0 (en) 2010-02-12 2010-02-12 Methods
PCT/GB2011/050233 WO2011098806A1 (en) 2010-02-12 2011-02-09 Proteins of the jak, stat, socs and pias families for use in the treatment hypercytokinemia or viral infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1002409.9A GB201002409D0 (en) 2010-02-12 2010-02-12 Methods

Publications (1)

Publication Number Publication Date
GB201002409D0 true GB201002409D0 (en) 2010-03-31

Family

ID=42110635

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1002409.9A Ceased GB201002409D0 (en) 2010-02-12 2010-02-12 Methods

Country Status (2)

Country Link
GB (1) GB201002409D0 (en)
WO (1) WO2011098806A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201400988SA (en) * 2011-10-21 2014-07-30 Glaxosmithkline Llc Compounds and methods for enhancing innate immune responses
US20170290821A1 (en) * 2014-09-22 2017-10-12 Japan Science And Technology Agency Anti-influenza virus agent and screening method for anti-influenza virus agent
CN109890965A (en) 2016-07-19 2019-06-14 匹兹堡大学联邦系统高等教育 Target the oncolytic virus of STAT3
CN112639084A (en) * 2018-08-16 2021-04-09 深圳市亦诺微医药科技有限公司 Methods and compositions for treating solid cancers and microbial infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369250A1 (en) * 2001-09-10 2003-03-10 Andrew Hoi-Tao Wong Novel anti-viral and anti-proliferative agents derived from stat1 transcription factor
JP2007516701A (en) * 2003-11-05 2007-06-28 アンスティテュ ドゥ ルシェルシュ プール ル デヴロップマーン (イ エール デ) Biomarkers resistant to human HIV infection and their biological applications
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
US20100015091A1 (en) * 2008-07-16 2010-01-21 Washington University In St. Louis Modified stat1 transgene that confers interferon hyperresponsiveness, methods and uses therefor

Also Published As

Publication number Publication date
WO2011098806A1 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
DK3342786T3 (en) Anti-dll3-antistof
AP3107A (en) 5-Alkynyl-pyrimidines
GB201010196D0 (en) Methods
EP2566479A4 (en) Azaindazoles
EP2640189A4 (en) 3-deutero-pomalidomide
DK3466977T3 (en) Anti-vla-4-antistoffer
EP2641891A4 (en) Pkc- activator
GB201007944D0 (en) Methods
GB201001760D0 (en) Dipenser
GB201001385D0 (en) Cable-tidies
GB201002409D0 (en) Methods
GB201001546D0 (en) Knocktop
GB201011367D0 (en) Methods
GB201015567D0 (en) Methods
GB201011010D0 (en) Methods
AU4822P (en) FlatwaxwhiteGL Chamelaucium uncinatum
AU4937P (en) FlatinsulGL Myoporum insulare
AU4931P (en) FlatwaxDarkGL Chamelaucium uncinatum
AU4932P (en) FlatwaxpinkGL Chamelaucium uncinatum
AU4536P (en) TB01 Tibouchina urvilleana
GB201006502D0 (en) Methods
GB201005761D0 (en) Methods
GB201000302D0 (en) Methods
GB201016459D0 (en) Methods
GB201020854D0 (en) Methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)